Previous literature has shown that Adropin is a known regulator of insulin sensitivity and glucose utilization, where multiple pre-clinical studies have shown increased insulin sensitivity, decreased hepatic gluconeogenesis, and more efficient oxidative phosphorylation when treating multiple diseases such as coronary atherosclerosis and diabetes in mouse models [4]. This evidence concerns the gene ENHO and diabetes mellitus.